Study title: Evaluation of Prednisone, Vincristine and Teniposide Combination Therapy for Refractory Childhood Lymphocytic Leukemia
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: TENIPOSIDE | |||||
| ATC code: L01CB02 | |||||
| Document link: teniposide 106-020.pdf | |||||
| Document date: 2011-09-21 | |||||
| Study number: CA106-020 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |